Search all ERS
Interstitial Lung Diseases
Respiratory Critical Care
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
ERJ Open Research
European Lung White Book
All ERS guidelines
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer
Taeyun Kim (Busan, South Korea)
International Congress 2019 – Lung cancer?
Lungs on fire
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Taeyun Kim (Busan, South Korea). A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer. International Congress 2019 – Lung cancer?
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
No comment yet.
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Does the lung function affect the survival time in patients with resected non-small cell lung cancer?
Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Does long treatment delay affect survival in metastatic non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Should there be a specific management for large cell neuroendocrine carcinoma?
Source: Annual Congress 2005 - Neuroendocrine tumours of the lung
The treatment of stage IV non-small cell lung cancer with target therapies
Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC?
Do cavitating non-small cell lung cancer patients have a more aggressive disease?
Source: Eur Respir J 2006; 28: Suppl. 50, 84s
A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema
Source: Annual Congress 2012 - Treatment of lung cancer
A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease
Source: International Congress 2018 – Lung cancer: personalised medicine
A novel biologic classification of non-small cell lung cancer
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
The role of palliative radiotherapy in locally advanced non small cell lung cancer
Source: Annual Congress 2007 - Therapy of lung cancer
A non-small cell lung cancer modelling by endogenous κ-ras manipulation
Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer
Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer